Medical Grand Rounds

*Presented by*

Yale School of Medicine, Department of Internal Medicine

Natalia Neparidze, MD

Assistant Professor of Medicine (Hematology)

“Evolving Therapeutic Landscape in Multiple Myeloma”

Iris Isufi, MD

Associate Professor of Medicine (Hematology); Co-Director Adult CAR T-Cell Therapy Program,

Hematology; Co-Leader, Cellular Therapy Disease Aligned Research Team (DART), Yale Cancer

Center; Co-Chair, Cellular Therapy (CT)-SAFE Committee, Yale Cancer Center

“Chimeric Antigen Receptor (CAR) Therapy for

Hematologic Malignancies”

**Date: September 30, 2021 Time: 8:30-9:30am**

**Location:** [**https://zoom.us/j/94896766303?pwd=UWFrcG9GNXMvcWZ3YU4ycUc5VEVSdz09**](https://zoom.us/j/94896766303?pwd=UWFrcG9GNXMvcWZ3YU4ycUc5VEVSdz09)

***There is no corporate support for this activity***

This course will fulfill the licensure requirement set forth by the State of Connecticut

**ACCREDITATION:**

The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

**TARGET AUDIENCE:**

**Attending physicians, house staff, fellows, medical students, PA’s**

Dr. Nepardize:

**NEEDS ASSESSMENT:**

Multiple myeloma accounts for almost 20% of hematological malignancies. Clinicians need to understand the pathophysiology of multiple myeloma, and know about the principles underlying diagnostic evaluation and treatment of this disease.

**LEARNING OBJECTIVES:**

1. Apply current concepts in diagnostic evaluation and pathophysiology of multiple myeloma

2. Improve knowledge of the current principles in clinical management of multiple myeloma

3. Understand novel therapeutic developments in the field of multiple myeloma

Dr. Isufi:

**NEEDS ASSESSMENT:**

Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the management of lymphoma, leukemia and multiple myeloma by providing a potentially curative approach for patients who are refractory to standard treatments. Clinicians need to understand the mechanisms underlying therapeutic and toxic effects of CAR T-cell therapy, and know about strategies for enhancing efficacy while reducing toxicity.

**LEARNING OBJECTIVES:**

1. Elucidate underlying principles of CAR T-Cell Therapy

2. Understand how CAR T-cells have revolutionized care for refractory lymphoma, leukemia and multiple myeloma

3. Examine class effects of the cell-mediated immune response (CRS and neurotoxicity) and management strategies

4. Introduce future directions in the field to improve efficacy and mitigate toxicity

**DESIGNATION STATEMENT**

*The Yale School of Medicine designates this live activity for 1 AMA PRA Category 1 Credit(s)™. Physicians should only claim the credit commensurate with the extent of their participation in the activity.*

**FACULTY DISCLOSURES:**

Course Director: Vincent Quagliarello, MD - None

Speaker: Natalia Nepardize, MD- Janssen; Research; Funding PI for clinical trial Glaxo-Smith-Kline; Research Funding; PI for clinical trial. Eidos Therapeutics; Scientific Committee Member, Diagnostic Committee for clinical trial

Iris Isufi, MD- Epizyme; Consulting Fee; Advisory Board. Gilead; Consulting/Speaker Fee; Advisory Board/Speaker Bureau

BEAM Therapeutics; Consulting Fee; Advisory Board

It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs.